- UCL Neuroscience rated top by research strength in the REF2014
- $5.9 million boost for SUDEP research
- Secret of tetanus toxicity offers new way to treat motor neuron disease
- Harm to others outweighs harm to self in moral decision making
- Auto anomaly detection for brain imaging awarded £1m grant
- Spinal surgery: OECs studies to start in 2015
- New brain tumour research Centre of Excellence is unveiled
- UCL awarded £13.5 million to advance medical research facilities
- UCL research helps paralysed man to recover function
- Stenting safe and effective for long-term stroke prevention
- Department of Clinical & Experimental Epilepsy re-designated as a WHO Collaborating Centre
- Leonard Wolfson Experimental Neurology Centre open evening
- Brain stimulation to improve cognition in dementia
- Professor Lees receives Jay Van Andel Award for Outstanding Research in Parkinson’s Disease
- Creating brain cells from skin to study Alzheimer's
- Queen Square authors prominent in Brain collection of classic articles
- Toxic proteins implicated in frontotemporal dementia and motor neurone disease
- GCH1 gene and Parkinson’s risk
- Double mutation linked to frontotemporal dementia
- Equation to predict happiness
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia
- Researchers test whether diabetes drug can help Parkinson’s patients
- Acute optic neuritis: a review and proposed protocol
- Hippocampal subfield size predicts the precision of memory recall
- Immune system implicated in dementia development
- UCL and Chiesi Group announce partnership to develop a novel therapeutic for birth asphyxia
- Professor Golay made a Fellow of the ISMRM
- The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
- Professor Rees wins UCLU Student Choice Teaching Award
- New epilepsy treatment offers ‘on demand’ seizure suppression
- Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
- Professor Dolan and Professor Friston elected to EMBO membership
- Vitamin B3 treatment for ataxia shows promise in first human trial
- Teaching Awards 2014
- Light-activated neurons from stem cells restore function to paralysed muscles
- UCL and Max Planck Society invest €5m to open world’s first computational psychiatry centre
- Successful launch of new annual leading edge neurology course
- Statins could help control MS
- Professor Hardy awarded Thudichum Medal by Biochemical Society
- Population Screening for vCJD Using a Novel Blood Test
- Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
- New partnership between UCLP brain tumour scientists and Brain Tumour Research
- Professor Hardy awarded Dan David Prize for work on the amyloid gene encoding APP
- NIHR award £650,000 for research into rare neurodegenerative and neuromuscular diseases
- Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
Published: Oct 10, 2014 5:54:41 PM
Published: Oct 22, 2014 9:52:00 AM
Published: Sep 16, 2013 1:37:21 PM
Published: Feb 24, 2014 2:53:53 PM
Published: Dec 19, 2014 2:44:33 PM
Published: Jul 30, 2014 1:47:13 PM
The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
5 June 2014
The new clinical trials unit was established through a £20 million award from the Wolfson Foundation to support research into neurological diseases.
LWENC operates 24hours a day through the partnership between the UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery (NHNN), UCLH at Queen Square.
Facility has been specifically designed to undertake experimental medicine
studies and early phase clinical trials (including first-in-man
studies) aiming at identifying potential disease modifying therapies
in the field of Neurology and Neurodegeneration. These include Alzheimer's
Disease, Parkinson’s disease, Huntington’s disease, Multiple Sclerosis, Stroke
and Prion disease.
It is very exciting to have reached this milestone. Our funding for the Centre reflects our commitment to supporting this vital area of science. There is a critical need to address the crisis of neurodegenerative disease facing an ageing population.
Paul Ramsbottom, Chief Executive, Wolfson Foundation
Location within the NHNN gives the LWENC unrivalled access to patients across age ranges, ethnicity and disease. The unit brings together the expertise of UCLH’s and UCL’s leading clinicians and scientists across a broad range of neurological and neurodegenerative diseases with renowned international collaborators and industry partners - the focus is on experimental medicine and early phase trials in patients and healthy volunteers.
We have exciting years ahead of us. Our mission is to provide world class clinical and governance expertise and infrastructure to expedite translational research and the early evaluation of novel treatments for neurodegenerative diseases. I, along with the rest of the LWENC team, am looking forward to this exciting venture at Queen Square.
Dr Vincenzo Libri, Head of the LWENC Clinical Facility
Strong working relationships are established between the LWENC and key service supports within UCLH and UCL, including the Joint Research Office, Pharmacy, Imaging and the Neuroscience Laboratories for blood and CSF biomarkers. Since it opened, the Centre has adopted more than 20 clinical trials in patients.
The Centre has three inpatient rooms and an infusion suite with three recliner chairs and has been designed to provide close monitoring in a relaxed and comfortable environment.
It also houses a consulting room and a laboratory for processing and storage of research samples.
The Centre is staffed with an experienced medical and nursing team who are fully trained in research governance and regulatory affairs and can provide administrative support for developing protocols and completing regulatory documents and contracts. All members of staff are GCP trained and hold different levels of training in medical emergencies, including Advanced Life Support (ALS) as standard for doctors and Immediate Life Support (ILS) as standard for nurses.
Immediate access ensures that patient safety is at the core of running successful clinical trials with safe drug administration and highly efficient monitoring and management of emerging clinical abnormalities and/or adverse reactions.
Edwina Saunders, Senior Research Nurse
The LWENC is located on the Ground Floor of the Albany Wing at the NHNN, giving immediate access to ICU and a 24-hour emergency response team who can arrive at the Centre within two minutes of an emergency. This, coupled with the experienced and fully trained in-house clinical team, ensures the successful set up of safe drug administration, advanced sampling and highly efficient monitoring/management of emerging clinical abnormalities and/or adverse reactions to study drugs.
Contact Details for queries:
- Manoj Maistry-Administrator: Manoj.email@example.com 0203448431
- Marivic Ricamara-Acting Lead Nurse: Marivic.firstname.lastname@example.org 07957479199
- Edwina Saunders-Senior Research Nurse: Edwina.email@example.com 07956727692
Page last modified on 14 may 14 15:12